William Blair analyst Sami Corwin has maintained their bullish stance on RARE stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sami Corwin has given his Buy rating due to a combination of factors that highlight Ultragenyx Pharmaceutical’s promising financial and operational performance. The company reported a slight revenue beat in the second quarter, with a total revenue of $166 million, surpassing both the firm’s estimate and consensus expectations. This growth was primarily driven by their key products, Crysvita and Dojolvi, which showed significant sales increases and new patient starts, particularly in Latin America where reimbursement agreements are in place.
Moreover, Ultragenyx has reiterated its revenue guidance for 2025, projecting between $640 million to $670 million, with Crysvita and Dojolvi expected to contribute significantly. Despite anticipating a modest rise in net cash used for operations due to timing delays in certain projects, the company remains on track to achieve GAAP profitability by 2027. Additionally, the successful early enrollment of the Phase III Aspire trial for Angelman syndrome treatment further supports the company’s growth prospects, enhancing investor confidence in its future performance.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $77.00 price target.
RARE’s price has also changed moderately for the past six months – from $45.780 to $28.050, which is a -38.73% drop .